Alkem Laboratories Ltd has revealed that its wholly owned subsidiary, Enzene Biosciences, was the target of a cyberattack affecting its U.S. operations, which led to a fraudulent transfer of funds. The company disclosed the Enzene Biosciences cyberattack in a regulatory filing on Thursday, May 15, 2025.
First seen on thecyberexpress.com
Jump to article: thecyberexpress.com/enzene-biosciences-cyberattack/
